[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
2-Jan-2014

[ | E-mail ] Share Share

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

JCI early table of contents for Jan. 2, 2014

Opioid tolerance and pain hypersensitivity associated with mTOR activation

Currently, opioids are the standard treatment for chronic pain. Patients on opioids for long periods of time become desensitized to these drugs or become paradoxically hypersensitive to pain (hyperalgesia); however, the adaptive mechanisms are not well understood. In this issue of the Journal of Clinical Investigation, Yuan-Xiang Tao and colleagues from the New Jersey Medical School at Rutgers University report that the protein mTOR, which is a global regulator of translation, plays a major role in morphine tolerance. Using animal models of opioid exposure, the authors found that mTOR is highly expressed in neurons of the dorsal horn, which is where opioid desensitization and hyperalgesia are thought to originate. Inhibition of mTOR activity with the drug rapamycin prevented and treated opioid tolerance and hyperalgesia in rats that had been exposed to chronic morphine injections. Chronic morphine injection increased activity of mTOR and two of its target proteins in the neurons of the dorsal horn. Furthermore, the authors determined that mTOR links a key opioid receptor to downstream proteins that are known to be involved in morphine tolerance and hyperalgesia, and that blocking mTOR reduced the production of these proteins. This study details a potential mechanism that drives opioid desensitization and hyperalgesia and suggests that targeting the mTOR pathway may improve pain management.

TITLE: Opioid receptor–triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia

AUTHOR CONTACT: Yuan-Xiang Tao
Rutgers, the State University of New Jersey, Newark, NJ, USA
Phone: 9739729812; Fax: 9739721664; E-mail: yt211@njms.rutgers.edu

View this article at: http://www.jci.org/articles/view/70236?key=8e6dfbd947463946789e


Doxorubicin-associated mitochondrial iron accumulation promotes cardiotoxicity

Doxorubicin is a widely used as a component of chemotherapy regimes; however, the use of doxorubicin is associated with severe cardiotoxicity. It is unclear exactly how doxorubicin promotes cardiotoxicity, but it has been proposed that doxorubicin-associated cardiomyopathy develops as the result of reactive oxygen species (ROS) production and iron accumulation. In this issue of the Journal of Clinical Investigation, Hossein Ardehali and colleagues at Northwestern University determined that doxorubicin accumulates within the mitochondria of cardiomyocytes and this accumulation promotes mitochondrial ROS production and iron accumulation. In a mouse model of doxorubicin-associated cardiotoxicity, overexpression of a protein that enhances mitochondrial iron transport reduced mitochondrial iron, ROS, and protected animals from doxorubicin-induced cardiomyopathy. Treatment of animals with dexrazoxane, which attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Furthermore, heart samples from patients undergoing doxorubicin therapy revealed higher levels of mitochondrial iron in patients with cardiomyopathies compared to patients without cardiac complications. These data suggest that therapies that limit mitochondrial iron accumulation have potential to limit doxorubicin-associated cardiotoxicity.

TITLE: Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

AUTHOR CONTACT: Hossein Ardehali
Northwestern University, Chicago, IL, USA
Phone: 312-503-2342; Fax: 312-503-0137; E-mail: h-ardehali@northwestern.edu

View this article at: http://www.jci.org/articles/view/72931?key=9b3d0d3c914bc63e96f7


ALSO IN THIS ISSUE

TITLE: Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

AUTHOR CONTACT: Yang-Xin Fu
The University of Chicago, Chicago, IL, USA
Phone: 773-702-0929; Fax: 773-834-8940; E-mail: yfu@midway.uchicago.edu

View this article at: http://www.jci.org/articles/view/67313?key=01e06eba76dd83aad5fb

TITLE: Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity

AUTHOR CONTACT: Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, Universit, Tokyo, , JPN
Phone: +81-3-58009092; Fax: +81-3-58408667; E-mail: kurokawa-tky@umin.ac.jp

View this article at: http://www.jci.org/articles/view/68101?key=9641bb0687c996b39b04

TITLE: Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal

AUTHOR CONTACT: William Kim
University of North Carolina, Chapel Hill, NC, USA
Phone: 919-966-4765; Fax: ; E-mail: wykim@med.unc.edu

View this article at: http://www.jci.org/articles/view/69804?key=6bc0c0f0192bf2f9b6e6

TITLE: Orexin neurons suppress narcolepsy via 2 distinct efferent pathways

AUTHOR CONTACT: Michihiro Mieda
Faculty of Medicine, Kanazawa University, Kanazawa, , JPN
Phone: 81762652171; Fax: 81762344224; E-mail: mieda@med.kanazawa-u.ac.jp

View this article at: http://www.jci.org/articles/view/71017?key=cc00eff4250e5b8f2900

TITLE: Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β–dependent cancer metastasis

AUTHOR CONTACT: Suyun Huang
UT MD Anderson Cancer Center, Houston, TX, USA
Phone: (713) 834-6232; E-mail: suhuang@mdanderson.org

View this article at: http://www.jci.org/articles/view/71104?key=319839e42c24c4354ad3

TITLE: OTX2 loss causes rod differentiation defect in CRX-associated congenital blindness

AUTHOR CONTACT: Anand Swaroop
National Eye Institute, Bethesda, MD, USA
Phone: (301) 435-5754; E-mail: swaroopa@nei.nih.gov

View this article at: http://www.jci.org/articles/view/72722?key=546e0c6bec3baf2197c4

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.